Viatris completed its acquisition of Pacira BioSciences on Nov. 17, 2026. The deal follows the definitive merger agreement announced in October.
Viatris (VTRS) agrees to buy Pacira BioSciences in a $36.50/share all-cash deal. Key points for investors on strategy, funding, and risks.
Viatris (VTRS) amends a £40B senior unsecured term loan; implications for refinancing, covenants and strategy amid FY2025 $14.3B revenues and $12.5B+ debt.